Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Fiche publication
Date publication
avril 2016
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle, Dr DEBIEUVRE Didier, Pr WESTEEL Virginie
Tous les auteurs :
Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, Ouafik L, Besse B, Rouquette I, Westeel V, Escande F, Monnet I, Lemoine A, Veillon R, Blons H, Audigier-Valette C, Bringuier PP, Lamy R, Beau-Faller M, Pujol JL, Sabourin JC, Penault-Llorca F, Denis MG, Lantuejoul S, Morin F, Tran Q, Missy P, Langlais A, Milleron B, Cadranel J, Soria JC, Zalcman G,
Lien Pubmed
Résumé
The molecular profiling of patients with advanced non-small-cell lung cancer (NSCLC) for known oncogenic drivers is recommended during routine care. Nationally, however, the feasibility and effects on outcomes of this policy are unknown. We aimed to assess the characteristics, molecular profiles, and clinical outcomes of patients who were screened during a 1-year period by a nationwide programme funded by the French National Cancer Institute.
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, genetics, Female, France, epidemiology, Gene Expression Profiling, Gene Rearrangement, Humans, Lung Neoplasms, genetics, Male, Middle Aged, Multivariate Analysis, Mutation, Phosphatidylinositol 3-Kinases, genetics, Prospective Studies, Proto-Oncogene Proteins B-raf, genetics, Proto-Oncogene Proteins p21(ras), genetics, Receptor Protein-Tyrosine Kinases, genetics, Receptor, Epidermal Growth Factor, genetics, Receptor, ErbB-2, genetics, Young Adult
Référence
Lancet. 2016 Apr;387(10026):1415-26